United States Veterinary AI Diagnostics Market

United States Veterinary AI Diagnostics Market Summary

As per Transpire Insight Analysis the United States Veterinary AI Diagnostics Market size is estimated at USD 375.7 Million in 2025 and is anticipated to reach USD 1193.8 Million by 2033, growing at a CAGR of 15.49% from 2026 to 2033.

The United States Veterinary AI Diagnostics Market helps vet practices make sense of radiographs, cytology, lab findings, and even patient records a bit quicker, which supports earlier detection while also cutting down the daily workload on clinicians. In the last 3–5 years, the market has kind of moved away from purely experimental algorithms, toward more embedded, clinic-ready diagnostic systems. AI-based imaging plus point of care platforms now tie in directly with well established veterinary workflows, you can see this in IDEXX’s AI enabled inVue Dx analyzer and in a range of newer imaging systems.

The COVID-19 pandemic, i n practice, became a big trigger, since it sped up pet adoption and also made staffing shortages feel worse, so many clinics had to juggle more cases with limited personnel, and that pressure didn’t go away. It really boosted the business logic for automation. Quicker image interpretation, more standardized testing, and smoother workflow integration let practices move through a higher volume of cases without needing to grow their clinical team at the same pace. That, in turn, supports wider adoption and helps drive recurring software, diagnostic, and equipment revenue.

United States Veterinary AI Diagnostics Market Size & Forecast:

• United States Veterinary AI Diagnostics Market Size 2025: USD 375.7 Million
• Expected Market Value 2033: USD 1193.8 Million
• Forecast CAGR: 15.49%
• Key Profile: IDEXX Laboratories, Zoetis Inc., Antech Diagnostics, Mars Veterinary Health, Heska Corporation, VetCT, SignalPET, Covetrus, Fujifilm Veterinary, GE HealthCare, Siemens Healthineers, Butterfly Network, Agfa HealthCare, Vetology AI, Esaote Group.

Key Market Insights

• North America still takes the lead, at 54.9% global market share in 2024, while the U.S. kind of stays the biggest country level contributor within the region.
• Asia Pacific looks like the quickest mover though, with growth expected to keep climbing across the 2025–2033 forecast span, as AI diagnostics adoption ramps up.
• In 2024, Software and services actually counted for 64.89% of the U.S. market share, it really makes the point that software-led revenue growth is the main engine.
• Hardware is still the second-biggest solution category, and its momentum is tied to the rollout of AI-enabled analyzers along with connected diagnostic devices , moving across clinics.
• When you look at applications, Imaging seems to be the fastest growth path all the way through 2033, and it’s largely supported by AI-assisted radiography, CT, MRI, and ultrasound interpretation.
• Pathology, on the other hand, was the leader in 2024, taking 34.56% globally, since digital pathology and automated cytology workflows kept expanding.
• In end use, veterinary clinics and hospitals led with 42.34% share in 2025 , showing that direct AI integration is being folded into everyday diagnostic routines.
• Research and academic institutes are the fastest-growing end-user group, as AI platforms keep getting adopted for validation, model development, and translational studies.
• IDEXX rolled out inVue Dx in 2024, and it uses deep-learning models trained on more than 10 million patient sample images, for rapid cytology.
• Zoetis launched AI Masses in 2025, adding AI-based screening for lymph-node and skin masses to Vetscan Imagyst.
• And Antech introduced AIS RapidRead, using AI-trained imaging tech to return veterinary radiology insights in minutes instead of days , or even hours.

What are the Key Drivers, Restraints, and Opportunities in the United States Veterinary AI Diagnostics Market?

Veterinary staffing constraints are still the main push driving AI diagnostics adoption. AI-enabled analyzers basically take manual microscopy, cytology, hematology, and that image-review part, then turn it into faster digital flows, sort of like collapsing steps that used to take longer. IDEXX’s inVue Dx, for example, delivers results in roughly 10 minutes, using deep-learning models trained on more than 10 million patient sample images, which is pretty striking. When turnaround is faster, clinics can decide on treatment during the appointment itself, that boosts equipment utilization, and it also opens up that recurring kind of software and diagnostic revenue stream. Zoetis has been expanding similar abilities across cytology and hematology, showing that AI is moving out of standalone trials, and into more routine point-of-care workflows.

The biggest structural restraint though is integration, plus ongoing validation. Veterinary AI needs high-quality labeled datasets, interoperability with practice-management systems and real clinical validation. Then there are also cybersecurity controls, and the unglamorous staff training, because the workflow has to actually stick. Accuracy worries remain big too, of course. In 2025 a North American veterinary survey found AI adoption at 39.2%, and “reliability” along with “accuracy” sat near the top of the barrier list, not exactly surprising. All of these things stretch deployment timelines and lift implementation costs, so vendors see revenue conversion later, while smaller practices may simply pause or delay. Finally, based on Transpire Insight review of regional procurement announcements and launch timing, supply chain concentration stays the most direct execution risk.

The next opportunity seems to sit in connected AI diagnostics, kind of where imaging, pathology, hematology, and specialist review all meet at once. Zoetis’ Virtual Laboratory, plus that more recent VitalRADS acquisition, shows a clear movement toward integrated AI-assisted diagnostic ecosystems, not just stand alone tools. In practice, these kinds of platforms can, in a way, blend automated analysis with a human in the loop kind of oversight , and it can kinda turn into subscription style revenue, interpretation fees , and also an ongoing data service income.

What Has the Impact of Artificial Intelligence Been on the United States Veterinary AI Diagnostics Market?

Artificial intelligence is kinda moving veterinary diagnostics away from hand-by-hand interpretation, toward automated and more connected decision support. In imaging, pathology, cytology, and hematology, machine-learning systems kinda sweep through samples, sort out abnormalities, rank what matters first, and produce early diagnostic output that then gets checked by clinicians. IDEXX inVue Dx leans on deep-learning models for cellular images, while Zoetis Vetscan Imagyst uses AI across fecal , blood , urine, skin, cytology and also mass-screening style workflows.

At the same time, predictive abilities are getting stronger. Machine-learning models can spot disease patterns across big diagnostic datasets, which helps with earlier clinical action. AI-enabled hematology platforms can categorize huge numbers of cells quickly, and the imaging systems will flag abnormalities for veterinary review. Zoetis’ Vetscan OptiCell looks at hundreds of thousands of cells during each run, measuring them against hundreds of parameters, so it supports fast point-of-care assessments.

Operational gains seem to revolve around turnaround time , some standardization, and staff productivity, you know the usual things. IDEXX reports about 10 minute results for in-clinical cellular analysis, which is meant to replace slower manual workflows that people were stuck with. Still, adoption has friction because integration costs stay high, and data quality can be kind of spotty in practice. Also veterinary datasets are usually smaller and far less standardized than many human health datasets. And model reliability, it can shift a lot across species , different equipment, distinct clinical settings, and even image quality levels.

Key Market Trends

• Since 2020 , AI diagnostics have sort of stretched out from parasite screening and moved into blood, urine, cytology skin and even mass analysis, with more places in the workflow.
• Then in 2024, IDEXX rolled out inVue Dx which kinda pushes cellular diagnostics away from slides, into slide free automated setups, and yes with AI supported in clinic readouts.
• During 2025, Zoetis also expanded Vetscan Imagyst with AI Masses, which extends automated cytology into lymph node and skin lesion screening, sort of a broader looking for problems angle.
• In 2025 Zoetis then launched Vetscan OptiCell , mixing AI plus microfluidics for faster point of care complete blood count analysis.
• By 2026, Zoetis took OptiCell further to 24 parameters, and added CHCM and plateletcrit so clinicians get a deeper in clinic hematology snapshot, more depth and less guesswork.
• Also in 2025, Zoetis opened a 32,000-square-foot Louisville reference laboratory that boosted the U.S. diagnostic capacity and the logistics backbone too, not just testing, like, overall.
• In 2025, peer-reviewed SignalPET research helped solidify clinical validation for AI assisted canine and feline radiograph interpretation, more evidence, less hype .
• By 2026, Zoetis was in the middle of pursuing VitalRADS acquisition, combining teleradiology, AI assisted reporting, imaging services, and specialist oversight that stays human paced.
• Software and services held 64.89% U.S. solution share in 2024 , which basically confirms the market is bending toward recurring digital diagnostic revenue.
• Even so, AI uptake is still selective, and a 2024 North American survey shows 39.2% adoption, while reliability concerns keep it from broader clinic deployment.

United States Veterinary AI Diagnostics Market Segmentation

By Component : 

Software has turned into a pretty major part of veterinary diagnostic deployment, because AI tools need digital spaces for image analysis, clinical decision help, and automated paperwork. Cloud services in particular back remote access, secure data storing, model updates, and the link between veterinary practices and diagnostic laboratories, kinda all in one place. Also AI platforms make it easier to merge imaging outputs, lab findings, and the patient file in a single workflow, no more zig zag steps that slow people down.

Yet hardware still matters, in practice really. AI turns on compatible analyzers and imaging gear sensors, also diagnostic instruments , so things run smoother in the lab. Imaging systems can power automated radiology reviews and ultrasound checks, while AI-enabled diagnostic devices speed up blood work, cytology, and pathology tests too.Analytics solutions and AI algorithms will likely become even more valuable as clinics push for quicker interpretation, more standardized outcomes, and smarter reuse of the diagnostic equipment they already have.

By Technology : 

Machine learning, and deep learning nowadays support lots of diagnostic functions, especially image classification, cell identification, and abnormality detection, it sort of all fits together. Computer vision helps radiology and pathology workflows too, because software can scan digital images at high speed, more or less without breaks. Neural networks back up pattern recognition across big diagnostic datasets and they tend to get better, as long as the training data grows and stays validated.

Predictive analytics can help with earlier disease detection and, sort of, clinical decision support too, mostly by sniffing out subtle patterns across lab outputs and imaging materials. Natural language processing can assist in arranging clinical notes, plus pulling out useful bits from veterinary records , even when the wording is kinda messy or disjointed.Generative AI and edge AI also bring newer opportunities, where edge processing enables faster local analysis, while generative systems can help with report preparation, clinical documentation, and overall diagnostic workflow management.

By Application : 

Medical imaging and radiology still matter a lot as application areas, because AI can parse huge volumes of digital images, then flag odd or abnormal findings for vet review, which is pretty useful in day to day practice. Disease detection really benefits from automated pattern recognition across blood tests, cytology, pathology, and also imaging data, in a kind of unified way. For pathology work, these tools additionally help with quicker cell classification, plus more steady screening during regular clinical routines, so clinicians can spend less time on repetitive labeling.

Telemedicine also keeps growing because it lets practices reach specialist interpretation, especially if they don't have dedicated radiology or pathology staff on site. Clinical decision support can blend the diagnostic observations with patient context and history, to help guide treatment planning. In the same direction, preventive care and companion animal diagnostics should gain more relevance as veterinary clinics move toward earlier screening approaches, while livestock monitoring can open the door to population level disease detection and broader health management strategies.

By End User : 

Veterinary hospitals and clinics are sort of a big deal in the story, because diagnostic AI can assist with daily imaging, pathology, hematology and cytology routines, you know. Diagnostic laboratories also gain a lot from automated analysis since high sample counts push everybody toward faster processing and steadier, repeatable interpretation, even when staff are busy. Research institutes and universities usually lean on AI platforms for clinical validation, dataset building, model testing, and other things, not to mention more focused veterinary research, even if the teams are smaller and the calendar is limited.

Livestock farms can use AI-enabled monitoring as well, to catch health shifts across wider animal populations , and that helps with earlier intervention before issues start to grow into bigger problems.Pet care centers, meanwhile, may rely on digital diagnostics as companion animal services become more technology-driven, which kind of changes how routine visits are handled. Government organizations and research bodies can also step in by backing validation, surveillance, and data initiatives that help increase confidence in AI-based veterinary diagnostic systems.

By Animal Type : 

Companion animals count as a pretty big application base, mainly because dogs and cats create a lot of diagnostic work across vet clinics and hospitals. AI assisted imaging , cytology pathology, and lab testing can make diagnostic paths shorter and help clinicians make quicker choices. For equine cases, there’s also room for more advanced imaging and specialized disease finding, in a way that feels almost tailored.

Then with livestock and poultry, the emphasis shifts toward watching whole populations, doing disease surveillance and spotting early health shifts sooner rather than later. Aquaculture meanwhile can lean on automated monitoring plus predictive analytics for disease control and better production efficiency. For exotic animals , zoo animals, and wildlife there are specialized chances too, where AI can help with image based checks and interpretation even when datasets are small and the clinical situations are more diverse.

What are the Key Use Cases Driving the United States Veterinary AI Diagnostics Market?

Medical imaging is still a major use case, and in practice veterinary hospitals, clinics, and diagnostic labs use AI to scan radiographs a lot sooner and flag abnormalities. The pull is pretty clear from buyers, they want shorter diagnostic cycles, steadier interpretation, and a more efficient use of specialist capacity, especially when access to veterinary radiologists is limited, or basically too thin in some regions.

On top of that, people are expanding into automated cytology and hematology workflows, mainly for veterinary clinics and diagnostic laboratories. Livestock farms too are moving toward AI-enabled monitoring, because it helps spot health shifts earlier. That in turn supports herd management and can cut losses that happen when intervention arrives too late, which is common in the field.

Looking ahead, the newer use cases involve AI-supported preventive screening for companion animals, plus population-level disease surveillance across poultry and aquaculture operations. These directions could pick up momentum as connected sensors become more common, cloud analytics get more mature, and validated diagnostic datasets keep improving through the forecast period.

Which Regions are Driving the United States Veterinary AI Diagnostics Market Growth?

The Western United States kind of acts like a big regional hub for veterinary AI diagnostics, powered by solid tech adoption , mature veterinary networks, and a cluster of AI-oriented companies. In practice, California and Texas keep a lot of veterinary activity moving, and tech pockets such as San Diego, plus Dallas, help with the build out of imaging, analytics, and diagnostic software. Firms like Vetology, SignalPET, and ImpriMed add extra technical reach across imaging and precision diagnostics, which basically makes a tight commercial ecosystem. As for leadership, it should stay supported through 2033, since veterinary groups keep pouring money into digital workflows, point of care systems , and AI helped interpretation.

Meanwhile, the Northeast feels more steady on revenue, thanks to established veterinary hospitals, diagnostic laboratories, universities, and research entities. Massachusetts and Maine bring meaningful animal health infrastructure, including IDEXX operations in Westbrook, Maine, and the already existing laboratory networks keep demand for diagnostic tech pretty consistent. Also, strong institutional purchasing plus research activity gives a buffer when discretionary veterinary visits do not behave as expected. Ongoing investment into laboratory automation and clinical diagnostics should keep revenue dependable across the forecast horizon.

The South looks like it has strong growth potential, because Texas plus nearby states kind of bring together large companion-animal populations, livestock work, veterinary practices and some serious technology investment. A Dallas-based SignalPET shows how the region is starting to play a bigger role in AI supported veterinary imaging, and also more clinical workflows. Livestock production creates extra openings for automated monitoring, early disease detection, and predictive analytics, beyond the whole companion-animal focus. Between 2026 and 2033 expanding clinic networks, and more rigorous AI validation will make room for tech vendors , diagnostic firms and investors who are searching for regional expansion.

Who are the Key Players in the United States Veterinary AI Diagnostics Market and How Do They Compete?

Competition in veterinary AI diagnostics stays kinda moderately concentrated around big animal- health and diagnostic companies, yet some specialized AI firms still bring in more focused solutions. The usual competitive levers are tech capability, diagnostic accuracy , workflow integration, turnaround time , and even access to veterinary data. The big incumbents tend to defend their existing clinic and laboratory networks with integrated platforms, while newer entrants show up with more narrow imaging, pathology, or clinical decision-support applications.

IDEXX looks different mainly because it ties together diagnostic instruments, laboratory services, software, and the actual clinical workflows. The 2024 launch of inVue Dx, it boosted their standing in automated cellular analysis by relying on deep-learning technology for fast in-clinic results. Zoetis competes with a wide diagnostic portfolio plus ongoing AI expansion, including Vetscan Imagyst and AI Masses. OptiCell, meanwhile, pushes AI-supported hematology for point of care workflows.

SignalPET, uh it’s built around veterinary radiology and kind of stands out by AI-assisted image interpretation. Instead of just doing it themselves, they do specialist supported reporting too, and they push adoption with clinical validation and imaging-focused services, so, yeah. Antech meanwhile brings a diagnostic laboratory scale plus AI-enabled imaging via AIS RapidRead, and the whole point is automation to shorten the radiology turnaround, like less delay. Zomedica goes another direction, with compact point-of-care systems such as TruView. They focus on clinics that want automated microscopy but in limited physical space, so it fits where it needs to fit.

Company List

• IDEXX Laboratories
• Zoetis Inc.
• Antech Diagnostics
• Mars Veterinary Health
• Heska Corporation
• VetCT
• SignalPET
• Covetrus
• Fujifilm Veterinary
• GE HealthCare
• Siemens Healthineers
• Butterfly Network
• Agfa HealthCare
• Vetology AI
• Esaote Group 

Recent Development News

In March 2026, Zoetis expanded Vetscan OptiCell capabilities to add cellular hemoglobin concentration mean and plateletcrit measurements. The update increased the platform to 24 parameters, strengthening AI-powered point-of-care hematology and bringing broader diagnostic testing into veterinary clinics.

Source: https://news.zoetis.com/

In April 2026, Techcyte raised $15 million in a capital round led by Van Tuyl Companies, with participation from Mayo Clinic and Zoetis. The investment will support expansion of Techcyte’s AI-powered digital pathology platform across veterinary and other diagnostic applications, strengthening development and commercialization capacity.

Source: https://techcyte.com/

What Strategic Insights Define the Future of the United States Veterinary AI Diagnostics Market?

In the next five to seven years the United States Veterinary AI Diagnostics Market is likely to move away from standalone picture interpretation tools, and instead go toward integrated clinical decision-support platforms that sit right inside veterinary practice-management and diagnostic workflows. You can see it happening because imaging volumes keep climbing, there are veterinarian shortages in various regions, people want faster diagnosis, and the multimodal AI capabilities are getting better, lot better.

That said there is a kind of not-so-obvious risk too, more like market concentration. Proprietary datasets, validation evidence, clinical integrations, and also regulatory experience can turn into real barriers. When that happens, a small group of providers might end up controlling key diagnostic infrastructure, even if the rest of the market keeps innovating.

On the opportunity side, multimodal systems look especially promising. Think radiographs, ultrasound, lab results, medical records, and longitudinal patient data all pulled together. This matters even more as interoperability standards improve across veterinary software stacks.

Market participants should focus on validated, interoperable platforms and on transparent performance monitoring, instead of racing each other purely on algorithm accuracy. If they invest strategically in clinical datasets, workflow integration, and evidence generation, it can build stronger commercial defensibility while also helping broader veterinary adoption take place smoothly.

United States Veterinary AI Diagnostics Market Report Segmentation

By Component

• Software
• Hardware
• AI Platforms
• Cloud Services
• Imaging Systems
• Analytics Solutions
• Sensors
• Diagnostic Devices
• AI Algorithms

By Technology

• Machine Learning
• Deep Learning
• Computer Vision
• Natural Language Processing
• Predictive Analytics
• Generative AI
• Edge AI
• Neural Networks
• Robotic AI

By Application

• Medical Imaging
• Disease Detection
• Pathology
• Radiology
• Telemedicine
• Preventive Care
• Livestock Monitoring
• Companion Animal Diagnostics
• Clinical Decision Support

By End User

• Veterinary Hospitals
• Veterinary Clinics
• Diagnostic Laboratories
• Research Institutes
• Livestock Farms
• Pet Care Centers
• Universities
• Government Organizations

By Animal Type

• Companion Animals
• Livestock
• Equine
• Poultry
• Aquaculture
• Exotic Animals
• Zoo Animals
• Wildlife